CCM
TNXP icon

Crew Capital Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Crew Capital Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$1.86K – 123
2024
Q1 		$1.86K Hold
3
– – ﹤0.01% 117
2023
Q4 		$4.03K Buy
+3
New +$4.83K ﹤0.01% 89

Other funds holding TNXP

Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Crew Capital Management's TNXP Position: Q2 2024 in Review

Crew Capital Management sold out of Tonix Pharmaceuticals (TNXP) in Q2 2024, closing a stake of 3 shares — an estimated $1.86K sold.

Crew Capital Management first reported a position in TNXP in Q4 2023 and held it in 2 quarters. The position peaked at $4.03K in Q4 2023. 13 funds tracked by Wall St. Rank hold TNXP as of Q2 2024.

  • Crew Capital Management reported no remaining Tonix Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Crew Capital Management sold 3 Tonix Pharmaceuticals shares in Q2 2024, an estimated $1.86K.
  • Crew Capital Management first reported a position in Tonix Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Crew Capital Management's Tonix Pharmaceuticals position peaked at $4.03K in Q4 2023.
  • 13 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2024.

Based on Crew Capital Management's 13F filing for Q2 2024, filed 26 Jul 2024.